Review Article
Year: 2023 | Month: July | Volume: 10 | Issue: 7 | Pages: 532-537
DOI: https://doi.org/10.52403/ijrr.20230765
A Review Article on Safety and Efficacy of Newer Oral Anticoagulants in the Treatment of Cerebral Venous Sinus Thrombosis
Alwy Joseph1, M V Prathvi1, Dr. Roshiny Thankam James2
1Pharm D Intern, Nazareth college of Pharmacy, Othera, Thiruvalla
1Pharm D Intern, Srinivas College of Pharmacy Mangaluru
2Assistant Professor, Department of Pharmacy Practice, Nazareth College of Pharmacy
Corresponding Author: Alwy Joseph
ABSTRACT
CVST (Cerebral Venous Sinus thrombosis) is an uncommon and complex illness with gender-specific origins and a wide range of clinical manifestations. It is also a rare kind of stroke that can be lethal if misdiagnosed or treated late. The reasons for this vary across industrialized and developing countries. It is distinguished by a clinical spectrum that is very varied, difficult diagnosis, various etiologies, and a prognosis that necessitates exceptional medical skills and a high suspicious score. When compared to vitamin K antagonists, NOACs had a roughly 50% decreased incidence of intracerebral hemorrhage. Direct oral anticoagulants have been the first-line medications used to treat this illness, but in this expanding world, newer oral anticoagulants such as Apixaban, Dabigatran, Rivaroxaban, and Edoxaban are being employed.
Keywords: Cerebral venous Sinus Thrombosis, Newer oral anticoagulants, Factor X A, Apixaban, Dabigatran, Rivaroxaban, Edoxaban
[PDF Full Text]